Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
The DOI matches its Crossref record; 158 of the 169 references it cites were found in a registry or an index.
Abstract
Objective: To update the "Testosterone Therapy in Men With Androgen Deficiency Syndromes" guideline published in 2010. Participants: The participants include an Endocrine Society-appointed task force of 10 medical content experts and a clinical practice guideline methodologist. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: One group meeting, several conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees and members and the cosponsoring organization were invited to review and comment on preliminary drafts of the guideline. Conclusions: We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men whose total T is near the lower limit of normal or who have a condition that alters sex hormone-binding globulin, we recommend obtaining a free T concentration using either equilibrium dialysis or estimating it using an accurate formula. In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. We recommend T therapy for men with symptomatic T deficiency to induce and maintain secondary sex characteristics and correct symptoms of hypogonadism after discussing the potential benefits and risks of therapy and of monitoring therapy and involving the patient in decision making. We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, prostate-specific antigen level > 4 ng/mL, prostate-specific antigen > 3 ng/mL in men at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer) without further urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia. We suggest that when clinicians institute T therapy, they aim at achieving T concentrations in the mid-normal range during treatment with any of the approved formulations, taking into consideration patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost. Clinicians should monitor men receiving T therapy using a standardized plan that includes: evaluating symptoms, adverse effects, and compliance; measuring serum T and hematocrit concentrations; and evaluating prostate cancer risk during the first year after initiating T therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TRT is also contra-indicated in people with (high risk of) prostate cancer, a history of breast cancer, thrombophilia, elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, and myocardial infarction or stroke within the last 6 months [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It suppresses spermatogenesis, and thus, cannot be used in patients with a desire to have children in the near future.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It may result in gynecomastia, acne, testicular atrophy and erythrocytosis.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“The Endocrine Society guideline emphasizes the importance of lifestyle changes in men with central hypogonadism and comorbidities [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“Hyperprolactinemia also suppresses the secretion of GnRH and the response of gonadotropins to GnRH secretion.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544
Self-citationAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Self-citationHeidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 1×
“culated from TT, SHBG, and albumin levels (23, 24).”
Harrison's Principles of Internal Medicine
Massarelli, J. J. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340300091039 · Cited by 1,132
Research works printed but not linked: 1
- Bhasin, 2015, Disorders of the testes and male reproductive system
Cited by
Items 1,501–1,600 of 1,733
Male hypogonadism – brief review of symptoms, types and ways of treatment
Tywanek, E., Trojanowska, P., Wronecki, J., Wiśniewska, K., & Łuczyk, R. J. (2021) · Journal of Education Health and Sport · doi:10.12775/jehs.2021.11.09.070
Pharmacoepidemiology of testosterone prescribing in Australia, 2010-2023
Gialouris, J. V., Hou, W., Lim, S., & Handelsman, D. J. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag158
Beltrán, C. S. G., García-Perdomo, H. A., & Ramos, A. F. G. (2026) · Actas Urológicas Españolas (English Edition) · doi:10.1016/j.acuroe.2026.501935
Fulco, E., Stingo, A., & Orlando, G. (2026) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2026.502841
A case of osteoporotic fracture leading to diagnosis of Klinefelter syndrome in a 76-year-old man
Shapiro, J., & Oprea, M. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag035
“Osteoporosis or low-trauma fracture in men warrants evaluation for secondary causes including screening for low testosterone [3].”
Lanfranco, F., Marinelli, L., & Nieschlag, E. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-61904-9_21-1
Testosterone Use and Abuse : Methodological Aspects in Forensic Toxicology and Clinical Diagnostics
Lood, Y. (2021) · Linköping University medical dissertations · doi:10.3384/diss.diva-173146
Castro, H. M., Knoblovits, P., Furcada, J. M., Vito, E. L. D., Suarez, S. M., & Costanzo, P. (2024) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2024.05.010
Hatta, S., Eguchi, Y., TAMURA, T., Sakamoto, S., Miyako, S., Toyoguchi, T., Shin, H., Kobayashi, T., Abe, Y., Saito, S., et al. (2026) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2026.06.015
da Silva, C. F., Neto, M. B., Fidale, T. M., Neto, A. M. D. M., Valentim‐Silva, J. R., de Carvalho, Y. K., Raimundo, R. D., de Abreu, L. C., Silva, R. P. M., & Penha‐Silva, N. (2023) · Sports Medicine and Health Science · doi:10.1016/j.smhs.2023.12.007
Alves, V. A. A., Silva, A. A. B., Bisneto, E. L. F., Macedo, H. F., Lima, G. S., Souza, L. G. P. S. D., Barbosa, P. E. A., & Júnior, P. F. D. M. (2026) · Cureus · doi:10.7759/cureus.104765
“Age-related hypogonadism, frequently associated with obesity, insulin resistance, and chronic inflammation, involves systemic metabolic dysregulation that may independently influence prostate cancer biology [10,11].”
Hayes, L. M., & Negrete, A. (2026) · doi:10.21019/9781582123875.ch45
Lanfranco, F., Marinelli, L., & Nieschlag, E. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-61901-8_21
March, K. L. (2026) · doi:10.21019/9781582123875.ch24
Hormone replacement therapy in andrology: current approaches, effectiveness, and risks
Makhachev, D. R., Musapirov, I. G., Magomedova, M. N., Abakarov, M. O., & Ametov, D. M. (2025) · International journal of Innovative Medicine · doi:10.33667/2782-4101-2025-2-8-10
Tamang, R., Disney, B., & Foster, J. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag082
“…with serum levels of total testosterone less than 230 ng/dL (SI: 8 nmol/L) and symptoms consistent with testosterone deficiency have a strong indication for TRT, while men with a total testosterone of up to 346 ng/dL (SI: 12 nmol/L) should be considered for a trial of TRT if symptomatic [11, 12].”
Rabbets, W. (2022) · South African General Practitioner · doi:10.36303/sagp.2022.3.1.0113
ความชุกและปัจจัยที่สัมพันธ์กับภาวะพร่องฮอร์โมนต่อมหมวกไตแบบทุติยภูมิในอดีตนักมวยไทย
พิชญ์ชัยประเสริฐ, ส., & สนับบุญ, ธ. (2017) · Chula Digiverse · doi:10.58837/chula.the.2017.1638
Chen, J., Wang, Z., Zhou, Y., Zhou, Z., & Yan, W. (2024) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2024.08.004 · Cited by 1
Male Fertility Preservation: A boon for young cancer survivors
Vickram, A. S., Dey, N., & Dhama, K. (2022) · Journal of Experimental Biology and Agricultural Sciences · doi:10.18006/2022.10(4).713.727
Classification of Andrological Disorders
Nieschlag, E., Tüttelmann, F., Kliesch, S., & Behre, H. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-31574-9_4 · Cited by 3
Chapter 29: Headache Disorders
Wheeler, J. S. (2026) · doi:10.21019/9781582123875.ch29
Gibney, J., Banerjee, I., & Ho, K. K. Y. (2022) · doi:10.1093/med/9780198870197.003.0005 · Cited by 1
Male hypogonadism and testosterone replacement therapy
Seal, L. (2025) · Medicine · doi:10.1016/j.mpmed.2025.07.004
Testosterone Therapy: a Panacea for Sexual Dysfunction in Men?
Helo, S., Thomas, P., & Tadros, N. N. (2018) · Current Sexual Health Reports · doi:10.1007/s11930-018-0151-8 · Cited by 1
Hypothalamo–Pituitary–Testicular Axis Function in Systemic Diseases and Effects of Medications
Wittert, G., Yeap, B. B., & Grossmann, M. (2022) · doi:10.1093/med/9780198870197.003.0492 · Cited by 1
Klinefelter Syndrome in adults: variability in clinical findings
Barbosa, M., Matta-Coelho, C., Fernandes, V., & Souto, S. B. (2021) · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo · doi:10.26497/ao200036
Laboratory testing in reproductive disorders
Woodworth, A. L., & McCudden, C. R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815499-1.00043-0
Huseynova, E., & Anani, W. Q. (2026) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2026.151040 · Cited by 1
Androgens and Anabolic Steroids
Hasan, M. S., & Elsaie, M. L. (2026) · Trends in andrology and sexual medicine · doi:10.1007/978-3-032-20623-7_14
Ferreira, M., Saraiva, P. O., Nunes, F., Cardoso, J., & André, M. E. (2026) · Cureus · doi:10.7759/cureus.116742
Sang, Z., Chen, J., Chen, W., Sun, B., Zhou, B., Liu, H., & Zhang, H. (2026) · Current Urology · doi:10.1097/cu9.0000000000000350
Optimizing evidence based primary care framework for inflammatory bowel disease
Dave, S. T., Varayil, J. E., Hurt, R. T., & Raffals, L. E. (2026) · Discover Medicine · doi:10.1007/s44337-026-00661-1
Alves, M. G., Moreira, R. J., Henriques, A. G., Ferreira, R. M., & Oliveira, P. F. (2026) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2026.61
Sarcopenia: From Global Consensus to Korean Implementation — A Narrative Review and Standpoint
Jang, G. Y., Ji, S., Jung, H., Baek, J. Y., Jang, I., Kim, K. M., Kim, M., Park, C. Y., Lee, K.-P., Ryu, D., et al. (2026) · Annals of Geriatric Medicine and Research · doi:10.4235/agmr.25.0182 · Cited by 1
Quarde, A. (2023) · Wiley eBooks · doi:10.1002/9781119863564.ch6
Leslie Neal-Boylan PhD, A. (2020) · Wiley eBooks · doi:10.1002/9781119603238.part11
Dawood, A. A., Al-Samarrai, R. R. H., & Husain, W. N. (2022) · AIP conference proceedings · doi:10.1063/5.0093482
Understanding the Controversy Regarding Treatment of Age-Related Testosterone Deficiency
Morgentaler, A. (2021) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2021.0006
“1 The controversy arises because professional society guidelines from prominent medical groups such as the Endocrine Society 4 and the American Urological Association, 5 as well as clinical recommendations from other groups, 6,7 make no such distinction based on etiology of TD, and recommend…”
Risks of Testosterone Treatment
Dobs, A. S., & Yalamanchi, S. (2022) · doi:10.1093/med/9780198870197.003.0490
Li, H.-M., Kou, J.-Q., Pu, Y.-J., et al. (2026) · Environment International · doi:10.1016/j.envint.2026.110477
Saad, F. (2022) · Springer eBooks · doi:10.1007/978-3-662-61417-4_9
Aversa, A., & Ilacqua, A. (2020) · Trends in andrology and sexual medicine · doi:10.1007/978-3-319-96376-1_16
Casals, G., Ferrer, R., Urgell, E., Escobar-Morreale, H. F., Argente, J., Sesmilo, G., & Biagetti, B. (2022) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2022.11.004
Wagner, A., Mjøsund, K., Komonen, R., Hackney, A. C., & Ihalainen, J. K. (2026) · Physiological Reports · doi:10.14814/phy2.70972
“Most low T athletes had T values within the normal clinical range, so our findings apply mainly to low-normal or functional low T , not clinical hypogonadism (Bhasin et al., 2018).”
Lubitz, S. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-76097-3.00020-x
SAGE-DM—Senescence-Associated Gluco-Endocrinopathy Diabetes Mellitus: comprehensive review
Szklarz, M., Wołos-Kłosowicz, K., Modzelewska, J., Górny, J. M., Modzelewski, R., & Matuszewski, W. (2026) · European journal of medical research · doi:10.1186/s40001-026-04445-2
“Treatment with testosterone gel for 1 year in 394 patients with symptomatic hypogonadism and TT levels 9.5 nmol/l gave rise to a reduction in their cholesterol and insulin levels, but had no effect on glycaemia, markers of inflammation, fibrinolysis or troponin compared to placebo [165].”
InfluentialLate-Onset Hypogonadism: An Overlooked Health Issue in Aging Men
Otoda, T. (2025) · Journal of Nihon University Medical Association · doi:10.4264/numa.84.6_271
Sleep disorders and testosterone deficiency in men
Khripun, I., & Beliaeva, E. V. (2025) · Urology Herald · doi:10.21886/2308-6424-2024-12-6-52-58
Schuppe, H.-C., & Köhn, F. (2022) · Springer eBooks · doi:10.1007/978-3-662-63709-8_83
Clift, A. K., Huang, D. R., Auerbach, N., Liu, V. N., Johnson, H. H., & Khera, M. (2025) · The Journal of Sexual Medicine · doi:10.1093/jsxmed/qdaf170 · Cited by 1
Unsafe Behaviors and Anabolic Steroid Use: implications for public health
Ip, E. J., & Silva, M. D. (2022) · Springer eBooks · doi:10.1007/978-3-030-67928-6_134-1
O’Brolchain, A., McAndrew, K., Newman, W., Young, D., Zyl, D. V., Dissanyake, R., Ebrahimi, E., & Griffin, K. (2026) · Endocrine · doi:10.1007/s12020-026-04722-4
“Ordering and results of pituitary imaging (either com - puterised tomography (CT) or magnetic resonance imaging (MRI) in patients with hypogonadism with inappropriately normal or low LH was assessed in line with Endocrine Soci - ety guidelines [16 ].”
InfluentialOlopade, O. B., Odeniyi, I. A., Adejumobi Sekinat, A., Ijeh Ifeyinwa, N., Fasanmade, O. A., & Atul, K. (2024) · International Archives of Endocrinology Clinical Research · doi:10.23937/2572-407x.1510036
The Lupus Damage Index Revision Program: Results From the Item Generation and Reduction Phases
Kundakci, B., Barber, M. R. W., Clarke, A. E., Johnson, S. R., Mak, A., Brunner, H. I., İnanç, M., Ramsey‐Goldman, R., Ruiz‐Irastorza, G., Ginzler, E. M., et al. (2026) · Arthritis Care & Research · doi:10.1002/acr.80102
Malich, D., & Vasylyshyn, A. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1901486
“According to the Endocrine Society guidelines, TRT should be avoided in men with a baseline hematocrit above 50% (Bhasin et al., 2018).”
Nieschlag, E., & Behre, H. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-31574-9_36 · Cited by 1
Clinical Diagnosis of Leydig Cell Dysfunction
Swerdloff, R. S., & Wang, C. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_16
Self-citationManagement of Testosterone Deficiency Syndrome
Park, H. J., Karthikeyan, V. S., & Chung, E. (2026) · Springer eBooks · doi:10.1007/978-3-032-12423-4_13
Arrested Puberty in a Young Adult With a Macroprolactinoma: Case Report and Literature Review
Sánchez, M., Otazú, M., Furtenbach, P., & Pineyro, M. M. (2025) · Case Reports in Endocrinology · doi:10.1155/crie/5388529
“For the diagnosis of hypogonadism in males, it is necessary to quantify serum levels of TT, which are expected to be decreased (less than 250 ng/dl), as seen in the case of this patient [16 – 18].”
Chapter 19: Geriatrics and Gerontology
Fixen, D. R. (2026) · doi:10.21019/9781582123875.ch19
Effect of androgen abuse on sleep apnea in men: a prospective cohort study
Verdegaal, T. J., Peeters, W., Bond, P., Machiels, H., de Ronde, W., & Smit, D. L. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02943-y
“Guidelines recommend caution in hypogonadal males due to the potential for worsening of pre-existing sleep-disor-dered breathing [24, 26].”
Majidipour, N., Sabbagh, S., Nazarian, H., Pourmotahari, F., & Azizolahi, B. (2025) · International Journal of Reproductive BioMedicine (IJRM) · doi:10.18502/ijrm.v23i10.20314 · Cited by 1
Reevaluating the Threshold for Low Total Testosterone
Arun, A. S., Durant, T. J. S., El-Khoury, J. M., & Krumholz, H. M. (2025) · Clinical Chemistry · doi:10.1093/clinchem/hvaf025
GÖZÜKAN, G., Topuz, B. T., Tufan, C., Saygılı, E. S., & Karakılıç, E. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03043-7
Jensterle, M., & Janež, A. (2026) · Andrology · doi:10.1111/andr.70264 · Cited by 1
“Although testosterone therapy remains justified for symptomatic men [ 4 ], prioritizing testosterone normalization as the principal therapeutic endpoint risks decoupling treatment from the underlying disease biology and its high multisystem burden, whereas GLP-1–based therapies offer more…”
Effect of Oral Bisphosphonates on Vertebral Fractures in Males Living with HIV: A Seven Year Study
Pezzaioli, L. C., Porcelli, T., Delbarba, A., Tiecco, G., Castelli, F., Cappelli, C., Ferlin, A., & Quirós-Roldán, E. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216526
“A normal range for LH was established between 1.5 and 9.4 mIU/mL [20,21].”
BackgroundInfluentialImaging Used in the Evaluation of NOA
Hegde, A. V., Toprak, T., & Chung, E. (2026) · Springer eBooks · doi:10.1007/978-3-031-99431-9_5
Hypogonadism and testosterone therapy in elderly men
Yeap, B. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00046-7
Male Hypogonadism and Aging: An Update
Iglesias, P., Núñez, A., & Díez, J. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-31501-5_9
Transgender Adult Males and Testosterone Hormone Therapy
Hohl, A., Lee, S. V. D. S., & Ronsoni, M. F. (2023) · Springer eBooks · doi:10.1007/978-3-031-31501-5_21
Testosterone Physiology and Diagnosis of Male Hypogonadism
Pozzi, E., Capogrosso, P., Boeri, L., Montorsi, F., Salonia, A., & Schlegel, P. N. (2025) · Springer eBooks · doi:10.1007/978-3-031-55405-6_48
Influence du sexe dans la susceptibilité aux hépatopathies métaboliques
Smati, S. (2019) · theses.fr (ABES) · doi:10.70675/01997f55za990z41e6z96baz8221de2a6281
Franks, A. S., & Yett, E. S. (2026) · doi:10.21019/9781582123875.ch39
Chan, A., & Sayer, M. (2026) · doi:10.21019/9781582123875.ch23
Brasher, C. (2026) · doi:10.21019/9781582123875.ch6
Benefits and Risks of Testosterone Replacement in the Older Man with Hypogonadism
Marcelli, M., & Mediwala, S. N. (2022) · Springer eBooks · doi:10.1007/978-3-030-99918-6_30
Chapter 1: Study Guide for the NAPLEX
Havrda, D. E. (2026) · doi:10.21019/9781582123875.ch1
Barrera, F. J., Raygoza-Cortez, K., García-Leal, M., Brito, J. P., Ospina, N. S., & Rodríguez‐Gutiérrez, R. (2021) · Endocrine · doi:10.1007/s12020-020-02592-y · Cited by 1
Self-citationโสธนนันทน์, ส. (2020) · Chula Digiverse · doi:10.58837/chula.the.2020.1332
Sommer, F. O., Szarvas, T., Baumhäkel, M., & Jäger, T. (2023) · Uro-News · doi:10.1007/s00092-023-5701-3
Ethical issues in the treatment of erectile dysfunction
Zámečník, L. (2026) · Urologie pro praxi · doi:10.36290/uro.2025.053
Galdiero, M., & Longhi, E. V. (2023) · Springer eBooks · doi:10.1007/978-3-031-31307-3_20 · Cited by 1
Current Diagnostic Criteria for Testosterone Deficiency Are Inadequate
Morgentaler, A. (2018) · European Urology Focus · doi:10.1016/j.euf.2018.08.014
(2023) · Aerospace Medicine and Human Performance · doi:10.3357/amhp.6259.2023
A Case Report on 46,XX Male Difference of Sex Development
de Assunção, G. V., Silva, B. T., Saraiva, M. N. M., et al. (2024) · Cureus · doi:10.7759/cureus.68741
“Before starting this treatment, clinicians should access the prior medical history of prostate or breast cancer, decompensated heart failure, prior stroke or acute myocardial infarction, sleep apnoea, thrombophilia, or a high hematocrit [11].”
BackgroundUnusual Cause of Severe Hyponatraemia
Hanafy, A., Holmes, S., & Rajeswaran, C. (2018) · Endocrine Abstracts · doi:10.1530/endoabs.59.ep96
The effects of dialysis modalities on sexual hormone levels in male patients
Atılgan, K. G., Aylı, M. D., Yalçındağ, A., Yay, F., Oğuz, E. G., Okyay, G. U., & Ebinç, F. A. (2020) · Journal of Health Sciences and Medicine · doi:10.32322/jhsm.685394
“Dialysis duration (months) 55 (13-151) 49 (5-156) 0.”
BackgroundIglesias, P. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2649164 · Cited by 1
“These changes are accompanied by a proinflammatory and proatherogenic profile (elevated CRP and homocysteine), which promotes endothelial damage and early atherogenesis [141–143].”
Aboelela, O., Asaad, S. A., Ajami, A.-M., Olca, J., Davies, S., Saad, J. A., Rizqou, S., Rubis, G. D., Dua, K., & Paudel, K. R. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101747
Bolat, M. S., Kocamanoğlu, F., Özbek, L. M., Şahin, B., Yılmaz, M., Gümüş, S., Dündar, C., & Aşçı, R. (2022) · Research Square · doi:10.21203/rs.3.rs-1363189/v1
Renck, A. C. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2023.tde-13062023-142212
TESTOSTERONE REPLACEMENT THERAPY IN MEN WITH HYPOGONADISM – REVIEW OF LITERATURE
Majewski, J., Wróblewska, O., Kaniecka, M., Karcz, A., Pająk, B., Dworniczak, M., Salash, S., Romaniuk, A., Bołdys-Żegocki, H., & Koza, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4391
Colombo, S., Amodeo, A., & Bonomi, M. (2026) · L Endocrinologo · doi:10.1007/s40619-026-01786-2
Sleep Disorders and Male Infertility: Integrated Mechanisms and Precision Therapeutic Strategies
Rong, J., & Dong, M. (2026) · Andrology · doi:10.1111/andr.70191 · Cited by 2
“TRT can rapidly correct hypogonadism, improve libido, and enhance quality of life [ 154 ], but it inhibits LH/FSH via negative feedback, reducing intratesticular testosterone and spermatogenesis [ 155 ].”
Chapter 18: Endocrine Disorders
George, C. M. (2026) · doi:10.21019/9781582123875.ch18
Wh, K., Kamaruddin, N. A., & Sukor, N. (2025) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.040.02.11
Chapter 34: Asthma and Chronic Obstructive Pulmonary Disease
McGiness, T. P., & Finch, C. K. (2026) · doi:10.21019/9781582123875.ch34
Male hypogonadism and its relationship with metabolic syndrome
Pinto, J. C., & da Costa, R. S. L. (2024) · Seven Editora eBooks · doi:10.56238/sevened2024.003-053
Metadata
- Authors
- Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Baylor College of Medicine (US)
- Massachusetts General Hospital (US)
- University of Southern California (US)
- VA Puget Sound Health Care System (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- University of Manchester (GB)
- Corresponding author
- Bhasin, Shalender
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-03-17
- Volume
- 103
- Issue
- 5
- Pages
- 1715-1744
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2791298691
- Cited by
- 1,736
- References
- 169
- Citations by year
- 2026: 263 · 2025: 196 · 2024: 198 · 2023: 199 · 2022: 240 · 2021: 221 · 2020: 201 · 2019: 157 · 2018: 56
- FWCI
- 126.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, male hypogonadism, androgen deficiency, sex hormone-binding globulin, secondary sexual characteristics, treatment monitoring, patient decision-making, pharmacokinetics, sleep apnea, thrombophilia, heart failure, lower urinary tract symptoms, fertility preservation
- MeSH terms
- Aged, Aged, 80 and over, Aging, Blood Chemical Analysis, Diagnostic Techniques, Endocrine, Endocrinology, Humans, Hypogonadism, Male, Middle Aged, Societies, Medical, Testosterone, Evidence-Based Medicine, Hormone Replacement Therapy, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.